Vulvovaginal Candidiasis Treatment Market Size - By Drug Class, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Vulvovaginal Candidiasis Treatment Market Size - By Drug Class, By Route of Administration, By Distribution Channel - Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Global Vulvovaginal Candidiasis Treatment Market Overview

According to SPER Market Research, the Global Vulvovaginal Candidiasis Treatment Market is estimated to reach USD 1.62 billion by 2032 with a CAGR of 4.61%. The vagina and the tissues close to the vulva's opening are both impacted by vulvovaginal candidiasis, a yeast infection. Candida species are the culprit behind it. Intense itching, inflammation, a thick, white discharge, and other signs of the illness are present. A single dose of the antifungal medication or the use of antifungal creams can cure a mild infection, but more extensive infections need more time-consuming therapy.

Impact of COVID-19 on the Global Vulvovaginal Candidiasis Treatment Market

The global expansion of the new coronavirus has had a minor influence on the market for treating vulvovaginal candidiasis. Due to the increased prevalence of candidiasis among COVID-19 patients, there was a considerable demand for medications to treat vulvovaginal candidiasis. This is due to an increase in bloodstream infections and infections related with healthcare, particularly in patients who have been hospitalized to hospitals.

Scope of the Report:

Market size available for years 2019-2032
Base year considered 2021
Forecast period 2022-2032

Segments covered By Drug Class, By Route of Administration, By Distribution Channel

Regions covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Astellas Pharma Inc., Basilea Pharmaceutica Ltd., Bayer AG, Bristol-Myers Squibb Company, Cadila Pharmaceuticals, Grupo Ferrer International S.A., Mycovia Pharmaceuticals, Inc., Pfizer, Inc., Scynexis, Inc.

Global Vulvovaginal Candidiasis Treatment Market Segmentation:

By Distribution Channel:Based on the Distribution Channel, Global Vulvovaginal Candidiasis Treatment Market is segmented as; Hospital Pharmacy, Online Pharmacy, Retail Pharmacy.

By Region:The global industry was dominated by North America. The area is anticipated to continue to grow steadily during the projection period, maintaining its leadership position. High disease prevalence, rising patient awareness, rising healthcare costs, and the existence of significant players in the area can all be contributed to this dominance.